why choose us

First received: July 14, 2022

Clinical Trial: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Alzheimer's Disease

Study Type: INTERVENTIONAL


Official Title: Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease

Brief Summary: The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).

Read more